Royal Bank of Canada reaffirmed their outperform rating on shares of Athenex (NASDAQ:ATNX) in a research report report published on Tuesday morning, The Fly reports.
A number of other equities analysts have also weighed in on ATNX. BidaskClub upgraded shares of Athenex from a strong sell rating to a sell rating in a research report on Tuesday, November 20th. JPMorgan Chase & Co. upgraded shares of Athenex from a neutral rating to an overweight rating and lowered their price target for the stock from $24.00 to $15.00 in a research report on Thursday, November 15th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of Hold and an average price target of $20.00.
ATNX stock opened at $11.39 on Tuesday. The stock has a market cap of $792.89 million, a PE ratio of -7.91 and a beta of 0.23. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.31 and a quick ratio of 3.86. Athenex has a 52 week low of $9.83 and a 52 week high of $20.90.
In other Athenex news, Director Song-Yi Zhang sold 32,240 shares of the business’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $11.85, for a total value of $382,044.00. Following the transaction, the director now directly owns 4,000 shares in the company, valued at approximately $47,400. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Johnson Yiu Nam Lau bought 10,000 shares of the firm’s stock in a transaction on Monday, March 11th. The stock was purchased at an average price of $11.78 per share, for a total transaction of $117,800.00. Following the completion of the acquisition, the chief executive officer now directly owns 2,917,422 shares in the company, valued at $34,367,231.16. The disclosure for this purchase can be found here. Insiders own 29.50% of the company’s stock.
A number of large investors have recently bought and sold shares of ATNX. Bank of America Corp DE boosted its holdings in Athenex by 34.4% in the 2nd quarter. Bank of America Corp DE now owns 56,822 shares of the company’s stock valued at $1,060,000 after purchasing an additional 14,530 shares during the last quarter. Private Advisor Group LLC acquired a new position in Athenex in the 3rd quarter valued at about $250,000. American Century Companies Inc. acquired a new position in Athenex in the 3rd quarter valued at about $1,894,000. BlackRock Inc. boosted its holdings in Athenex by 3.2% in the 3rd quarter. BlackRock Inc. now owns 3,582,578 shares of the company’s stock valued at $55,673,000 after purchasing an additional 110,332 shares during the last quarter. Finally, Tower Research Capital LLC TRC acquired a new position in Athenex in the 3rd quarter valued at about $146,000. Institutional investors own 31.81% of the company’s stock.
Athenex Company Profile
Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.
Featured Article: What is a blue-chip stock?
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.